A dynamic Bayesian network model for self-monitoring of rheumatoid arthritis

Ali Fahmi¹, Amy MacBrayne², William Marsh¹, Frances Humby²

- ¹ School of Electronic Engineering and Computer Science, Queen Mary University of London, London, E1 4NS, UK
- ² The William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK

Abbreviated abstract: We propose a dynamic Bayesian network (DBN) model to self-monitor the disease activity of rheumatoid arthritis (RA). The structure and parameters of DBN are learnt based on the knowledge elicited from domain experts and supported by literature. The model represents the interactions between disease manifestation factors and provides promising results in predicting disease activity and the occurrence of flare-up. In the next phase, we will involve treatment in the model.

Related publications:

- E. Kyrimi, S. McLachlan, K. Dube, M. R. Neves, A. Fahmi, N. Fenton, Artificial Intelligence In Medicine (submitted) (2020)
- A. Fahmi et al, International Conference on Health Informatics, 2020 (accepted paper)



Previous work and challenge

One of the major challenges of managing chronic diseases like RA is the lack of self-monitoring tools. Clinicians usually schedule quarterly follow-up visits to monitor the activity of disease and prescribe medications. Patients can call clinicians in emergency or if a flare-up happens. Some guidelines are proposed to improve the quality of care delivery; however they do not address the discontinuity of monitoring and care. We collaborate with two rheumatologists to capture the current care pathway for RA monitoring. We drew the pathway of RA, as shown in Fig. 1, which contains the main activities (rectangular shapes) and decisions (diamond shapes). It has three entries: the regular clinic visit by a rheumatologist, the review of test results by a clinician, and when patient feels flare-up.




Fig 1. Pathway of RA monitoring with clinician and patient entries

Rheumatologists check signs, symptoms, and blood test results of patients and calculate their disease activity score 28 (DAS28) to categorise them into high, moderate, low, and remission. Patients receive their prescription of medications and steroids based on their DAS28. This process repeats every 3 to 6 months. We intend to create a DBN model which can predict RA disease activity and flare-ups. This model can be used for a self-monitoring system that patients enter their signs and symptoms in a weekly manner and clinicians can control their disease activity remotely.

Design







Evidence variables extracted from care pathway



Latent variables derived from experts, literature, and care pathway

Dependencies
between variables
and parameters of variables
learnt from experts and literature

| Variable Type | Variable | States | Description |
|---------------|----------------------|------------------------|----------------------------------|
| Monitoring | Disease State | Low, Moderate, High | Categorised DAS28 |
| | Disease | Deteriorating, Stable, | Disease progression trend |
| | Progression | Improving | |
| | Flare-up | None Miner Major | Occurrence of a Flare-up |
| | Occurrence | None, Minor, Major | |
| | Flare-up | Short, Medium, Long | Duration of a flare-up |
| | Duration | Short, Mediam, Long | |
| | Flare-up | Rare, Some, Many | Frequency of flare-up occurrence |
| | Frequency | Mare, Some, Marry | in 3 months |
| | Overall Flare -up | None, Mild, Severe | Patient's overall flare-up |
| | | | combining flare-up occurrence, |
| | | | duration, and frequency |
| | Overall Flare- | Deteriorating, Stable, | Overall flare-up trend |
| | up Trend | Improving | |
| | Overall Disease | Good, Alarm, Poor | Disease being overall under |
| | Control | Good, Alaitii, Fooi | control, on alarm, or unmanaged |
| Advice | Advice | Call Hospital, | Advice based on overall disease |
| | | Attend Appointment, | control, overall flare-up trend, |
| | | Self-manage | and disease progression trend |




Latent variables involved in building model structure and parameters

| Variable Type | Variable | States | Description |
|---------------|----------|------------------------|--------------------------------------|
| Signs | TJC | None, Some, Many | Number of tender joints examined by |
| | | None, Some, Many | pressing between two fingers |
| | SJC | None, Some, Many | Number of swollen joints observed by |
| | | None, Some, Many | patient |
| Symptoms | GH | Low, Medium, High | Patient's general health |
| | Fatigue | Low, Medium, High | Patient's feeling of fatigue |
| | Pain | Low, Medium, High | Patient's feeling of pain |
| | HAQ | Mild, Moderate, Severe | Patient's disability measured by |
| | | | health assessment questionnaire |
| Blood results | ESR | Normal, Moderate, High | ESR measured in a patient's blood |
| | CRP | Normal, Moderate, High | CRP measured in a patient's blood |

Table 1. List of evidence variables – namely signs, symptoms, and serology results – , their states and descriptions.

Evidence variables involved in model






Table 2. List of latent variables for monitoring, an advice variable, and their states and descriptions.

Results




Fig 3. Improving scenario with High, Medium, and Low states (black, red, and green, respectively) for Disease State, Disease control, and Overall Flare-up.

Fig 4. Worsening scenario with High, Medium, and Low states (black, red, and green, respectively) for Disease State, Disease control, and Overall Flare-up.

Fig 5. Fluctuating scenario with High, Medium, and Low states (black, red, and green, respectively) for Disease State, Disease control, and Overall Flare-up.

We defined three scenarios – namely, improving, worsening, and fluctuating – containing SJC, TJC, GH, ESR, and CRP evidences. These scenarios illustrate the changes of the major outcome variables: Disease State, Disease Control, and Overall Flare-up.

Two extreme scenarios of improving and worsening merely show the ability of the model to estimate the activity of disease. The fluctuating scenario expresses an active disease in the beginning which is put into remission after 12 weeks. However, it includes one major but short flare-up between 24th and 27th

weeks and later a minor but long flare-up during 42nd to 49th weeks. We will add treatment variables – medication type, medication dose, and side-effects – and will further evaluate the ability of this model to monitor the disease and provide helpful advice.